Injectable hemostatic and anti-adhesion hydrogel and its preparation method and application
By introducing sulfonate betaine and polyethylene glycol into polylactic acid and blending with gelatin and urea, an injectable hemostatic and anti-adhesion hydrogel is prepared, which solves the difficulty of existing hemostatic materials to quickly at the disaster site. Controls the problems of adhesions that are prone to cause adhesions during bleeding and wound healing in the body, achieving rapid hemostasis and anti-adhesion effects.
Patent Information
- Application Number
- CN202410212266.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-02-27
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-02-27
AI Technical Summary
Existing hemostasis materials are difficult to effectively control incompressible internal organ bleeding at the disaster site, and it is easy to cause adhesions during the wound healing process, resulting in pain and complications of the injured.
Develop an injectable hemostatic and anti-adhesion hydrogel, which produces strong anti-adhesion and anti-adhesion properties by introducing sulfonate betaine and polyethylene glycol in polylactic acid and blending with gelatin and urea. Hydrogel.
The hydrogel can quickly and effectively bind to irregular wounds, sealing the wound and achieving hemostasis effect, while avoiding adhesions with tissues, promoting wound healing and reducing complications.
Smart Images

Figure CN118141972B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of hemostatic materials, and in particular relates to an injectable hemostatic and anti-adhesion hydrogel and a preparation method and application thereof. Background Art
[0002] Disasters and emergencies can easily cause external trauma to the human body and are likely to lead to death. Among them, massive blood loss is the main factor in pre-hospital deaths. Blood loss of more than one-third of the human body will induce a series of systemic reactions such as shock. Therefore, in order to minimize the number of early deaths, it is necessary to intervene quickly after injury and stop bleeding caused by trauma. Among traumatic hemorrhages, non-compressible hemorrhage injuries are particularly difficult to diagnose and treat in a timely manner, and are still a global problem. Non-compressible hemorrhage injuries can be divided into non-compressible trunk hemorrhage after trauma to major organs or vascular systems in the chest or abdomen according to their anatomical location, non-compressible junctional bleeding at the junction of the limbs and trunk (including the groin, gluteus maximus area, axilla and neck base above the inguinal ligament), and non-compressible limb bleeding secondary to penetrating injuries to the upper or lower extremity blood vessels. Studies have shown that non-compressible trunk hemorrhage is the largest source of traumatic bleeding (67.3%), and the treatment of such patients is the main challenge and core issue facing the construction of trauma emergency care.
[0003] Treatment methods for such casualties include immediate on-site bleeding control and damage control resuscitation with blood product transfusion as the main method, but both require a high degree of timeliness. Traditionally used dressing and powder hemostatic materials are difficult to effectively act on the hemostatic site, making it extremely difficult to achieve pre-hospital bleeding control, which can lead to death. Therefore, in addition to establishing systematic treatment standards at disaster sites and improving damage control methods, it is also necessary to actively carry out research on new technologies for hemostasis and protection of important organs to ensure that the casualties receive timely and effective pre-hospital treatment.
[0004] Current hemostatic products and most of the research focus on hemostasis of superficial wounds, achieving rapid hemostasis by absorbing wound fluid and physically sealing. Gauze products such as Quikclot combat gauze are widely used, but their own hemostatic effect is poor and their wound adaptability is weak. Xstat is a syringe containing multiple small pieces of compressed chitosan sponges. The sponges are injected into the wound to quickly absorb liquid and swell to achieve the effect of closing the wound. However, this adsorption can cause blood loss in the tissues around the wound and cause secondary damage. Compont, a spray product with cyanoacrylate as the main ingredient, can quickly absorb water into a shell and stop bleeding after contact with liquid, but its degradation products contain toxic components, which will cause serious biosafety risks. If the dosage is not properly controlled, it will also cause tissue hardening. In addition, there are powder and gel hemostatic materials, but these products often do not have good treatment measures for bleeding from non-compressible internal organs.
[0005] In addition, after the initial hemostasis and healing of the wound in the body, the imbalance between fibrin deposition and dissolution can easily cause adhesion between the wound and the contacting tissue, adding pain to the injured.
[0006] Therefore, it is necessary to study a material that can quickly and effectively stop bleeding when used for pre-hospital treatment of organ bleeding at disaster sites, and will not adhere to wound tissue, thereby promoting wound healing. Summary of the invention
[0007] In order to solve the above technical problems, the present invention provides an injectable hemostatic and anti-adhesion hydrogel and a preparation method and application thereof. The injectable hydrogel of the present invention can adapt to irregular wound morphology and quickly and effectively combine with the wound, thereby sealing the wound while exerting a hemostatic effect and will not adhere to tissues.
[0008] The present invention is specifically achieved through the following technical solutions.
[0009] The first object of the present invention is to provide a method for preparing an injectable hemostatic and anti-adhesion hydrogel, comprising the following steps:
[0010] In a protective gas atmosphere, modified polylactic acid was prepared by ring-opening reaction using sulfonic acid propyl diethanol methyl ammonium inner salt as initiator, Sn(Oct)2 as catalyst, L-lactide and polyethylene glycol as raw materials;
[0011] The modified polylactic acid is dissolved in ethanol, and the gelatin aqueous solution, the dissolved modified polylactic acid and urea are mixed and stirred to prepare a hydrogel.
[0012] In some embodiments of the present invention, the mass ratio of L-lactide, polyethylene glycol, sulfonate propyl diethanol methyl ammonium inner salt and Sn(Oct)2 is 9.0-12.0:0.9-1.2:2.25-3.0:0.045-0.06, and the molecular weight of polyethylene glycol is 400-6000.
[0013] In some embodiments of the present invention, the temperature of the ring-opening reaction is 130° C. and the reaction time is 20-26 h.
[0014] In some embodiments of the present invention, after the ring-opening reaction is completed, the reaction system is cooled to room temperature, chloroform is added to dissolve, ice methanol is precipitated, and dried to obtain the modified polylactic acid.
[0015] In some embodiments of the present invention, ethanol is anhydrous ethanol, and the usage ratio of modified polylactic acid and anhydrous ethanol is 0.4-0.6 g:10 mL; in the mixed stirring system, the concentration of gelatin aqueous solution is 20-30% w / v, the content of urea is 2-10% w / v, and the mass ratio of modified polylactic acid and gelatin is 1:10.
[0016] In some embodiments of the present invention, the mixing temperature is 60° C. and the mixing time is 90 min.
[0017] In some embodiments of the present invention, sulfonic acid propyl diethanol methyl ammonium inner salt is prepared by the following steps:
[0018] Dissolve N-methyldiethanolamine in acetone to prepare solution 1;
[0019] Dissolve 1,3-propane sultone in acetone to prepare solution 2;
[0020] At room temperature, solution 1 and solution 2 were mixed to prepare sulfonic acid propyl diethanol methyl ammonium inner salt.
[0021] In some embodiments of the present invention, in solution 1, the amount ratio of N-methyldiethanolamine to acetone is 2.5-3.5 g:10 mL;
[0022] In solution 2, the dosage ratio of 1,3-propane sultone and acetone is 2.75-3.75 g:10 mL;
[0023] The volume ratio of solution 1 to solution 2 is 1:1.
[0024] The second object of the present invention is to provide an injectable hemostatic and anti-adhesion hydrogel prepared by the preparation method.
[0025] The third object of the present invention is to provide the use of the injectable hemostatic and anti-adhesion hydrogel in hemostatic materials.
[0026] Compared with the prior art, the present invention has the following beneficial effects:
[0027] The present invention introduces zwitterionic sulfobetaine into polylactic acid and copolymerizes it with polyethylene glycol to prepare modified polylactic acid, adds hydrophilic segments to the polymer to improve water solubility, and enhances anti-protein adhesion ability, and further blends the modified polylactic acid with gelatin through small molecule hydrogen bond dissociation agent urea to prepare injectable hydrogel. The hydrogel can adapt to irregular wound morphology and quickly and effectively bind to the wound, and exert hemostatic effect while sealing the wound. In addition, urea can promote the formation of internal bonding of the hydrogel, and gradually releases due to gradient diffusion in a humid environment, so that the hydrophobic segments inside the hydrogel are exposed to the surface, promoting the formation of the anti-adhesion interface of the hydrogel. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 The present invention provides a flow chart (A) and a principle diagram (B) for preparing the injectable hemostatic and anti-adhesion hydrogel.
[0029] Figure 2These are the Fourier transform infrared spectroscopy (FTIR) and nuclear magnetic resonance hydrogen spectrum (1HNMR) characterization results of the materials prepared in Example 1; wherein A is the nuclear magnetic hydrogen spectrum of MPS, B is the nuclear magnetic hydrogen spectrum of PMP, and C is the Fourier transform infrared spectrum of each material.
[0030] Figure 3 The scanning electron microscope (SEM) and water contact angle test results of the hydrogel prepared in Example 1; wherein A is the SEM image of the PMP-30 hydrogel and the surface of the PMP-30 hydrogel after water is sprayed on the surface, B and C are the water contact angle test results of the PMP-30 hydrogel and the surface of the PMP-30 hydrogel after water is sprayed on the surface, respectively, and D is the contact angle data.
[0031] Figure 4 In the figure, A shows that L929 cells were inoculated onto the surface of the hydrogel prepared in Example 1 which was treated with deionized water to form a film, and the adhesion and proliferation of the cells were observed after 24 hours of culture; B is a characterization diagram of the in vivo anti-adhesion performance detection of the hydrogel prepared in Example 1; C is the adhesion score of each group in B.
[0032] Figure 5 This is a test of the hemostatic performance of the hydrogel prepared in Example 1 on a rat animal model. DETAILED DESCRIPTION
[0033] In order to enable those skilled in the art to better understand and implement the technical solution of the present invention, the present invention is further described below in conjunction with specific embodiments and drawings, but the embodiments are not intended to limit the present invention.
[0034] The experimental methods and detection methods described in the following embodiments are conventional methods unless otherwise specified; the reagents and materials are commercially available unless otherwise specified.
[0035] For pre-hospital treatment of organ bleeding at disaster sites, the materials currently used often have poor hemostatic effects. To this end, the present invention focuses on the research of rapid and effective hemostatic materials for pre-hospital treatment of organ bleeding at disaster sites, and provides an injectable hemostatic and anti-adhesion hydrogel. The hydrogel has injectability and strong anti-adhesion ability, can adapt to irregular wound morphology and quickly and effectively combine with the wound, sealing the wound while exerting a hemostatic effect.
[0036] In addition, after the initial hemostasis and healing of the wound in the body, the imbalance between fibrin deposition and dissolution can easily cause adhesion between the wound and the contacting tissue, adding pain to the injured. Therefore, the protection and anti-protein function of the material in the wound healing process have also received attention. By effectively protecting the wound and preventing adhesion between tissues and organs, it can promote rapid wound healing and prevent the occurrence of complications such as chronic pain, intestinal obstruction, and bacterial infection.
[0037] Therefore, the hydrogel provided by the present invention can not only quickly stop bleeding during pre-hospital treatment of organ bleeding at a disaster site, but also will not adhere to tissues.
[0038] Specifically, the hydrogel preparation method provided by the present invention is as follows: Figure 1 As shown, the following steps are included:
[0039] In a protective gas atmosphere, modified polylactic acid was prepared by ring-opening reaction using sulfonic acid propyl diethanol methyl ammonium inner salt as initiator, Sn(Oct)2 as catalyst, L-lactide and polyethylene glycol as raw materials;
[0040] The modified polylactic acid is dissolved in ethanol, and the gelatin aqueous solution, the dissolved modified polylactic acid and urea are mixed and stirred to prepare a hydrogel.
[0041] When artificial materials or drug carriers come into contact with organisms and blood, immune reactions or thrombus formation will occur. The cell membrane-like structure formed by zwitterionic polymers gives them excellent biocompatibility and anti-adhesion properties. Polylactic acid (PLA) is a type of high molecular biodegradable polyester. Due to its good mechanical properties, it is widely used in tissue engineering and anti-adhesion. However, its own hydrophobicity limits its research in the field of hemostatic materials. Zwitterionic polymers with different branched structures such as sulfonate betaine, phosphobetaine and carboxylate betaine groups are used as anti-adhesion surface modification of implant materials in vivo due to their unique anti-protein properties. Among them, the structure of sulfonate betaine (PS) is similar to that of bovine bile in the human body, with high hydrophilicity and biocompatibility. Gelatin is derived from the hydrolysis of collagen and is a mixture of polypeptide molecules composed of various amino acids. Its surface is rich in NH3 sites. Its chain structure has a unique motif of arginine-glycine-aspartic acid (RGD) sequence, which can significantly increase adhesion to tissue cells.
[0042] The present invention selects polylactic acid, sulfobetaine, polyethylene glycol and gelatin as the main components of the hydrogel. Among them, polylactic acid and gelatin are both FDA-approved raw materials that can be used for pharmaceutical products. Polylactic acid is a biodegradable material with lactic acid as the main raw material, with good biocompatibility and degradability, and can be used to prepare bioengineering scaffolds; and due to its hydrophobic main chain structure, it has an anti-adhesion effect. Gelatin is a mixture extracted and purified from collagen-rich animal tissues. It has a unique adhesion motif and can effectively promote the adhesion of hydrogels to the surfaces of human tissues, organs, etc. When gelatin is dissolved in water to form a gel, it has a rich porous structure, which can quickly absorb blood overflowing from the wound, enrich coagulation factors, and accelerate wound hemostasis. Polyethylene glycol is a high molecular polymer with good lubricity and antifouling properties, which can be used for surface modification of medical polymer materials, improve the biocompatibility of the material surface in contact with blood, and effectively reduce protein adsorption and bacterial and cell adhesion. Sulfobetaine is a polymer with zwitterions, has good anti-plasma protein properties, and has an anti-adhesion effect.
[0043] In some embodiments of the present invention, the mass ratio of L-lactide, polyethylene glycol, sulfonate propyl diethanol methyl ammonium inner salt and Sn(Oct)2 is 9.0-12.0:0.9-1.2:2.25-3.0:0.045-0.06, and the molecular weight of polyethylene glycol is 400-6000.
[0044] In some embodiments of the present invention, the temperature of the ring-opening reaction is 130° C. and the reaction time is 20-26 h.
[0045] In some embodiments of the present invention, after the ring-opening reaction is completed, the reaction system is cooled to room temperature, chloroform is added to dissolve, ice methanol is precipitated, and dried to obtain the modified polylactic acid.
[0046] In some embodiments of the present invention, ethanol is anhydrous ethanol, and the usage ratio of modified polylactic acid and anhydrous ethanol is 0.4-0.6 g:10 mL; in the mixed stirring system, the concentration of gelatin aqueous solution is 20-30% w / v, the content of urea is 2-10% w / v, and the mass ratio of modified polylactic acid and gelatin is 1:10.
[0047] In some embodiments of the present invention, the mixing temperature is 60° C. and the mixing time is 90 min.
[0048] In some embodiments of the present invention, sulfonic acid propyl diethanol methyl ammonium inner salt is prepared by the following steps:
[0049] Dissolve N-methyldiethanolamine in acetone to prepare solution 1;
[0050] Dissolve 1,3-propane sultone in acetone to prepare solution 2;
[0051] At room temperature, solution 1 and solution 2 were mixed to prepare sulfonic acid propyl diethanol methyl ammonium inner salt.
[0052] In some embodiments of the present invention, in solution 1, the amount ratio of N-methyldiethanolamine to acetone is 2.5-3.5 g:10 mL;
[0053] In solution 2, the dosage ratio of 1,3-propane sultone and acetone is 2.75-3.75 g:10 mL.
[0054] The final form of the product provided by the present invention is an injectable hydrogel, which is prepared by introducing zwitterionic sulfobetaine into polylactic acid and copolymerizing it with polyethylene glycol, adding a hydrophilic segment to the polymer to improve water solubility and enhance anti-protein adhesion ability. The modified polylactic acid is further blended with gelatin by using urea, a small molecule hydrogen bond dissociator, and the urea can promote the formation of internal bonding of the hydrogel and gradually release it due to gradient diffusion in a humid environment, so that the hydrophobic segments inside the hydrogel are exposed to the surface, promoting the formation of the anti-adhesion interface of the hydrogel.
[0055] The content of the present invention is specifically described below through the following examples and comparative examples. The prepared hydrogel is named PMP-X, wherein X represents the mass concentration of gelatin (X%).
[0056] Example 1
[0057] A method for preparing an injectable hemostatic and anti-adhesion hydrogel, such as Figure 1 As shown, the following steps are included:
[0058] (1) Synthesis of initiator sulfonic acid propyl diethanol methyl ammonium salt
[0059] Sulfonic acid propyl diethanol methyl ammonium salt (MPS) was prepared by reacting N-methyldiethanolamine (MDEA) with 1,3-propane sultone (1,3-PS). Specifically, 2.5 g MEDA and 2.75 g 1,3-PS were dissolved in 10 ml acetone, and the two solutions were slowly added dropwise through a constant pressure funnel and stirred for 20 hours. After the reaction, the prepared white product was collected and repeatedly washed with acetone and filtered under reduced pressure three times, and stored in a vacuum drying oven.
[0060] (2) Synthesis of sulfobetaine-modified polylactic acid
[0061] The prepared MPS was used as an initiator for the ring-opening reaction of L-lactide (LLA), and L-lactide and polyethylene glycol (PEG) were cross-linked to prepare betaine-modified polylactic acid (PMP). Specifically, 12.0g LLA, 1.2g PEG (average molecular weight range 400-6000) and 3.0g MPS were placed in a 100ml round-bottom flask, evacuated and circulated through N2 for three times, and 0.06g Sn(Oct)2 was added with a syringe after heating to 130°C in an oil bath, and the reaction was continued for 24h with heating and stirring. After the product was cooled to room temperature, chloroform was added to dissolve it, ice methanol was precipitated, and finally a white product was obtained by vacuum drying. The composition and structure of the synthesized product were determined by Fourier transform infrared spectroscopy (FTIR) and nuclear magnetic resonance hydrogen spectrum (1H NMR).
[0062] (2) Preparation of betaine-modified polylactic acid hydrogel
[0063] 0.4 g of PMP was swelled and dissolved in 10 ml of anhydrous ethanol, gelatin was dissolved in 60°C deionized water at 30% w / v, stirring was continued for 60 min, dissolved PMP and 4% w / v urea were added, the mass ratio of PMP to gelatin was 1:10, stirring was continued for 90 min. The prepared hydrogel was named PMP-X, where X represents the mass concentration of gelatin (X%). The hydrogel prepared in this example is PMP-30.
[0064] Example 2
[0065] A method for preparing an injectable hemostatic and anti-adhesion hydrogel, such as Figure 1 As shown, the following steps are included:
[0066] (1) Synthesis of initiator sulfonic acid propyl diethanol methyl ammonium salt
[0067] Sulfonic acid propyl diethanol methyl ammonium salt (MPS) was prepared by reacting N-methyldiethanolamine (MDEA) with 1,3-propane sultone (1,3-PS). Specifically, 3.5 g MEDA and 3.75 g 1,3-PS were dissolved in 10 ml acetone, and the two solutions were slowly added dropwise through a constant pressure funnel and stirred for 24 hours. After the reaction, the prepared white product was collected and repeatedly washed with acetone and filtered under reduced pressure three times, and stored in a vacuum drying oven.
[0068] (2) Synthesis of polylactic acid modified with sulfobetaine
[0069] The prepared MPS was used as an initiator for the ring-opening reaction of L-lactide (LLA), and L-lactide and polyethylene glycol (PEG) were cross-linked to prepare betaine-modified polylactic acid (PMP). Specifically, 9.0g LLA, 0.9g PEG (average molecular weight range 400-6000) and 2.25g MPS were placed in a 100ml round-bottom flask, evacuated and circulated through N2 for three times, and 0.045g Sn(Oct)2 was added with a syringe after heating to 130°C in an oil bath, and the reaction was continued for 20h with heating and stirring. After the product was cooled to room temperature, chloroform was added to dissolve it, ice methanol was precipitated, and finally a white product was obtained by vacuum drying. The composition and structure of the synthesized product were determined by Fourier transform infrared spectroscopy (FTIR) and nuclear magnetic resonance hydrogen spectrum (1H NMR).
[0070] (2) Preparation of betaine-modified polylactic acid hydrogel
[0071] 0.6 g of PMP was swelled and dissolved in 10 ml of anhydrous ethanol, gelatin (Gel) was dissolved in 60°C deionized water at 20% w / v, and stirring was continued for 60 min. The dissolved PMP and 2% w / v urea (Urea) were added, and the mass ratio of PMP to gelatin was 1:10, and stirring was continued for 90 min. The prepared hydrogel was named PMP-X, where X represents the mass concentration of gelatin (X%). The hydrogel prepared in this example is PMP-20.
[0072] Example 3
[0073] A method for preparing an injectable hemostatic and anti-adhesion hydrogel, such as Figure 1 As shown, the following steps are included:
[0074] (1) Synthesis of initiator sulfonic acid propyl diethanol methyl ammonium salt
[0075] Sulfonic acid propyl diethanol methyl ammonium salt (MPS) was prepared by reacting N-methyldiethanolamine (MDEA) with 1,3-propane sultone (1,3-PS). Specifically, 3.0 g MEDA and 3.0 g 1,3-PS were dissolved in 10 ml acetone, and the two solutions were slowly added dropwise through a constant pressure funnel and stirred for 24 hours. After the reaction, the prepared white product was collected and repeatedly washed with acetone and filtered under reduced pressure three times, and stored in a vacuum drying oven.
[0076] (2) Synthesis of polylactic acid modified with sulfobetaine
[0077] The prepared MPS was used as an initiator for the ring-opening reaction of L-lactide (LLA), and L-lactide and polyethylene glycol (PEG) were cross-linked to prepare betaine-modified polylactic acid (PMP). Specifically, 10.0g LLA, 1.0g PEG (average molecular weight range 400-6000) and 3.0g MPS were placed in a 100ml round-bottom flask, evacuated and circulated with N2 for three times, and 0.06g Sn(Oct)2 was added with a syringe after heating to 130°C in an oil bath, and the reaction was continued for 26h with heating and stirring. After the product was cooled to room temperature, chloroform was added to dissolve it, ice methanol was precipitated, and finally a white product was obtained by vacuum drying. The composition and structure of the synthesized product were determined by Fourier transform infrared spectroscopy (FTIR) and nuclear magnetic resonance hydrogen spectroscopy (1H NMR).
[0078] (2) Preparation of betaine-modified polylactic acid hydrogel
[0079] 0.5 g of PMP was swelled and dissolved in 10 ml of anhydrous ethanol, gelatin was dissolved in 60°C deionized water at 25% w / v, stirring was continued for 80 min, dissolved PMP and 10% w / v urea were added, the mass ratio of PMP to gelatin was 1:10, stirring was continued for 90 min. The prepared hydrogel was named PMP-X, where X represents the mass concentration of gelatin (X%). The hydrogel prepared in this example is PMP-25.
[0080] Example 4
[0081] A method for preparing an injectable hemostatic and anti-adhesion hydrogel, such as Figure 1 As shown, the following steps are included:
[0082] (1) Synthesis of initiator sulfonic acid propyl diethanol methyl ammonium salt
[0083] Propyl diethanol methyl ammonium sulfonate (MPS) was prepared by reacting N-methyldiethanolamine (MDEA) with 1,3-propane sultone (1,3-PS). Specifically, 3.5 g MEDA and 2.75 g 1,3-PS were dissolved in 10 ml acetone, and the two solutions were slowly added dropwise through a constant pressure funnel and stirred for 22 hours. After the reaction, the prepared white product was collected and repeatedly washed with acetone and filtered under reduced pressure three times, and stored in a vacuum drying oven.
[0084] (2) Synthesis of sulfobetaine-modified polylactic acid
[0085] The prepared MPS was used as an initiator for the ring-opening reaction of L-lactide (LLA), and L-lactide and polyethylene glycol (PEG) were cross-linked to prepare betaine-modified polylactic acid (PMP). Specifically, 12.0g LLA, 0.9g PEG (average molecular weight range 400-6000) and 3.0g MPS were placed in a 100ml round-bottom flask, evacuated and circulated with N2 for three times, and 0.06g Sn(Oct)2 was added with a syringe after heating to 130°C in an oil bath, and the reaction was continued for 20h with heating and stirring. After the product was cooled to room temperature, chloroform was added to dissolve it, ice methanol was precipitated, and finally a white product was obtained by vacuum drying. The composition and structure of the synthesized product were determined by Fourier transform infrared spectroscopy (FTIR) and nuclear magnetic resonance hydrogen spectroscopy (1H NMR).
[0086] (2) Preparation of betaine-modified polylactic acid hydrogel
[0087] 0.5 g of PMP was swelled and dissolved in 10 ml of anhydrous ethanol, gelatin was dissolved in 60°C deionized water at 30% w / v, stirring was continued for 90 min, dissolved PMP and 10% w / v urea were added, the mass ratio of PMP to gelatin was 1:10, stirring was continued for 90 min. The prepared hydrogel was named PMP-X, where X represents the mass concentration of gelatin (X%). The hydrogel prepared in this example is PMP-30.
[0088] Comparative Example 1
[0089] Commercially available anti-adhesion products: Cebitu surgical anti-adhesion fluid.
[0090] Comparative Example 2
[0091] Commercially available gelatin sponge.
[0092] Comparative Example 3
[0093] Commercial gauze.
[0094] The performance of the materials in the above examples and comparative examples is characterized below.
[0095] (i) The material prepared in Example 1 was tested by nuclear magnetic resonance hydrogen spectrum (1H NMR) and Fourier transform infrared spectroscopy (FTIR).
[0096] like Figure 2 As shown in Figure A, in the NMR hydrogen spectrum of MPS, 2.2ppm at b, 2.95ppm at a, and 3.55ppm at c all show the hydrogen chemical shift of propane sultone, which is different from the chemical shift of hydrogen on the nitrogen atom in MDEA, thus indicating that MPS was successfully synthesized. Figure 2In the H NMR spectrum of PMP shown in Figure B, the g peak at 1.40 to 1.70 ppm shows the chemical shift of methyl and methylene groups in the PLA polymer chain, and the h peak at 5.06 ppm shows the absorption peak at the end of the PLA chain. The I peak at 2.23 ppm confirms that MPS is grafted into PLA and PMP is successfully synthesized.
[0097] exist Figure 2 In the infrared spectrum shown in C, 2900~3000cm -1 The peak between them is the stretching vibration of C-H at 1756cm -1 The absorption peak belongs to the stretching vibration of C=O, proving the existence of ester group, 1382cm -1 The peak is a characteristic peak of methyl, confirming the structure of polylactic acid; an additional peak at 1190 cm -1 With 1075cm -1 The peak is the main characteristic peak of sulfonic acid group, which proves that sulfobetaine has been successfully synthesized into the structure of polylactic acid; 3287cm in PMP-30 -1 The left and right peaks are the amine peaks of gelatin, 1622 cm -1 With 1527cm -1 The peak at is the amide I–III absorption band, which is the conformational sensitive band of peptides and proteins. The shift of the peak also proves that intermolecular hydrogen bonds are formed between gelatin and PMP.
[0098] (ii) The material prepared in Example 1 was characterized by scanning electron microscopy (SEM) and water contact angle test.
[0099] like Figure 3 As shown, A is the SEM image of PMP-30 hydrogel and the surface of PMP-30 hydrogel after water spraying. It can be seen that the microscopic morphology of the hydrogel has a uniform and rich pore structure. The uniformity of the hydrogel pore structure helps to absorb blood and excess tissue exudate around the wound space, promote hemostasis, and provide air permeability for a moist environment that is conducive to cell proliferation. In particular, after spraying water on the hydrogel surface, a smooth film-like structure was observed, which is conducive to the subsequent anti-adhesion effect. B and C are the water contact angle test results of PMP-30 hydrogel and the surface of PMP-30 hydrogel after water spraying, respectively. D is the contact angle data. The water contact angle test results show that the hydrogel surface changes from hydrophilic to relatively hydrophobic after water treatment, proving that water induces the rapid reconstruction of PLAMPS segments on the hydrogel surface.
[0100] (III) L929 cells were inoculated into complete culture medium containing PMP-30 hydrogel film treated with deionized water. Complete culture medium without additional ingredients was used as a control. After 24 hours of culture, the adhesion and proliferation of cells were observed.
[0101] like Figure 4 As shown in A, the L929 cells in the control group adhered normally and filled the wells. After washing with PBS, the cells were still tightly adhered, while no cells were observed on the surface of the PMP-30 hydrogel. These results indicate that the unique film-forming property and anti-protein effect of PMP-30 can effectively prevent the adhesion and proliferation of fibroblasts and avoid postoperative adhesion problems.
[0102] (IV) The rat cecal abrasion model was selected to further verify the anti-adhesion property of the hydrogel in vivo. The model was established by rubbing the corresponding areas of the traumatic abdominal wall and cecum, and commercially available hydrogel was used as a positive control.
[0103] like Figure 4 In the model group shown in B, there was a large area of irremovable adhesion between the cecum and the abdominal wall, and the adhesion score exceeded 3; using the commercially available anti-adhesion product, Cebitu Surgical Anti-Adhesion Fluid, as a control, the main ingredient of which is carboxymethyl chitosan, the commercially available hydrogel group observed multiple small adhesions, which may be due to the fact that the injected hydrogel did not completely cover the worn area, or flowed to other parts of the body, resulting in poor anti-adhesion effect at the worn area. Figure 4 As shown in C, there was almost no adhesion in the PMP-30 hydrogel group, and the adhesion score was lower (P < 0.001 compared with the control group). The cecum could be separated freely from the abdominal cavity, and no adverse tissue damage was observed at the wear site.
[0104] like Figure 4 As shown in B, H&E stained sections showed that a large number of inflammatory cells appeared in the adhesion area in the model group and the commercial hydrogel group, and fibrous deposition was produced around the wear site in the control group in Masson staining, proving the formation of adhesion between the cecum and the abdominal wall. Slight adhesion between the cecum was also observed in the commercial hydrogel group. In contrast, the H&E stained sections of the PMP-30 hydrogel group contained fewer inflammatory cells, and due to its biodegradable properties, very little material remained in the wear site, and no obvious fibrin deposition was observed in Masson staining. These results prove that PMP-30 hydrogel has better anti-adhesion properties, and the polymer anti-adhesion film formed based on water treatment and the anti-protein effect of sulfobetaine work together during wound healing.
[0105] (V) Hemostatic effect of hydrogel
[0106] The hemostatic effect of the hydrogel material was first verified by coagulation inversion experiment, dynamic coagulation experiment and in vitro whole blood coagulation experiment to verify the hemostatic effect of the hydrogel in vitro. Coagulation occurred after about 180s of co-incubation with gauze and whole blood, while the blood of the control group remained flowing for more than 200s. The whole blood coagulation time of PMP-30 hydrogel is similar to that of commercially available gelatin sponge, and the fastest time is about 80s to form a completely stable self-supporting gel. In a further coagulation inversion experiment, the EP tube was inverted every 15s after adding whole blood to each group for observation. The PMP-30 hydrogel can coagulate blood in 45s without falling off. The coagulation index (BCI) represents the coagulation speed of the material. The lower the BCI, the better the coagulation effect. The PMP-30 group has obvious blood clot adsorption within 30s, and the BCI value is lower than that of other groups. The hemostatic effect of the hydrogel is affected by the gelatin content in the hydrogel. After the blood is absorbed through the porous structure of the hydrogel, the electrostatic interaction between gelatin and zwitterions and plasma promotes blood coagulation. At the same time, the PMP-containing hydrogel with improved hydrophilicity shows a better hemostatic effect than the PM hydrogel, which may be due to less hydrophobic interface.
[0107] We simulated the liver injury bleeding model by cutting a 1.5 cm wound with a surgical blade at 0.5 cm from the bottom of the liver, and used commercial gauze and gelatin sponge as the control group. After the different hemostatic materials were used to treat the hemostasis, the hemostasis time and blood loss were recorded. Figure 5 As shown in the figure, the gauze group bled profusely, with an average blood loss of 1249.17 mg and a hemostasis time of 170 seconds. After the PMP-30 hydrogel was injected and covered on the wound, it immediately sealed the wound, and then the blood coagulated rapidly, and the bleeding stopped quickly. The average blood loss of the hydrogel was 596 mg, and hemostasis was achieved in about 33 seconds, which was significantly less than that of the gauze group.
[0108] After hemostasis, the liver was returned to the abdominal cavity for suture. After 14 days of feeding, no death occurred in the two groups of rats. The rats were killed and the abdominal cavity was opened to observe and evaluate the adhesion. Obvious adhesions were found inside the rats in the gauze group. The liver wound formed adhesions with the abdominal wall and intestinal membrane that were difficult to peel off, with a score of 2-3 points. In the PMP-30 hydrogel experimental group, the liver did not adhere or only had slight adhesions with the abdominal wall, which could be easily separated, and the adhesion score was significantly lower than that of the gauze group. We believe that the smooth anti-adhesion membrane formed by the water treatment of PMP-30 hydrogel effectively prevents the contact between the wound tissue and other tissues in the body and reduces the occurrence of tissue adhesion in the body. Even if the hydrogel is completely degraded and disappears in the body, the degradation product containing zwitterionic sulfobetaine can still prevent protein adhesion and provide continuous and effective protection around the wound. The results of H&E and Masson staining showed that no tissue necrosis occurred at the surface scratch site and more collagen fibers were generated. The inflammatory response decreased at d14, and new granulation tissue was observed around the wound, proving that the hydrogel had a good hemostatic effect and would not cause additional adverse effects on the wound.
[0109] The hydrogels prepared in the remaining embodiments are similar to those in Embodiment 1 and are not described in detail herein.
[0110] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, they are also intended to be included.
Claims
1. A method for preparing an injectable hemostatic and anti-adhesion hydrogel, characterized in that: The following steps are involved: In a protective gas atmosphere, modified polylactic acid was prepared by ring-opening reaction using sulfonic acid propyl diethanol methyl ammonium salt as an initiator, Sn(Oct)2 as a catalyst, L-lactide and polyethylene glycol as raw materials; The modified polylactic acid is dissolved in ethanol, and the gelatin aqueous solution, the dissolved modified polylactic acid and urea are mixed and stirred to prepare a hydrogel; In the mixed and stirred system, the concentration of the gelatin aqueous solution is 20-30% w / v, the content of urea is 2-10% w / v, and the mass ratio of the modified polylactic acid to the gelatin is 1:
10.
2. The preparation method according to claim 1, characterized in that: The mass ratio of L-lactide, polyethylene glycol, sulfonic acid propyl diethanol methyl ammonium salt and Sn(Oct)2 is 9.0-12.0:0.9-1.2:2.25-3.0:0.045-0.06, and the molecular weight of polyethylene glycol is 400-6000.
3. The preparation method according to claim 1, characterized in that: The temperature of the ring-opening reaction is 130°C and the reaction time is 20-26h.
4. The preparation method according to claim 1, characterized in that: After the ring-opening reaction is completed, the reaction system is cooled to room temperature, chloroform is added to dissolve, ice methanol is precipitated, and dried to obtain the modified polylactic acid.
5. The preparation method according to claim 1, characterized in that: The ethanol is anhydrous ethanol, and the usage ratio of the modified polylactic acid and anhydrous ethanol is 0.4-0.6 g:10 mL.
6. The preparation method according to claim 1, characterized in that: The mixing temperature was 60°C and the mixing time was 90 min.
7. The preparation method according to claim 1, characterized in that: Sulfonic acid propyl diethanol methyl ammonium inner salt is prepared by the following steps: Dissolve N-methyldiethanolamine in acetone to prepare solution 1; Dissolve 1,3-propane sultone in acetone to prepare solution 2; At room temperature, solution 1 and solution 2 were mixed to prepare sulfonic acid propyl diethanol methyl ammonium inner salt.
8. The preparation method according to claim 7, characterized in that: In solution 1, the dosage ratio of N-methyldiethanolamine and acetone is 2.5-3.5 g:10 mL; In solution 2, the dosage ratio of 1,3-propane sultone and acetone is 2.75-3.75 g:10 mL; The volume ratio of solution 1 to solution 2 is 1:
1.
9. An injectable hemostatic and anti-adhesion hydrogel, characterized in that: The invention is prepared by the preparation method according to any one of claims 1 to 8.
10. Use of the injectable hemostatic and anti-adhesion hydrogel according to claim 9 in the preparation of hemostatic and anti-adhesion materials.
Citation Information
Patent Citations
Biodegradability hydrogel controlled-release preparation and its preparation method and application
CN101283966A
